Literature DB >> 31121174

Identification of proteomic signatures associated with COPD frequent exacerbators.

Pengbo Sun1, Rui Ye1, Cuihong Wang1, Shuang Bai1, Li Zhao2.   

Abstract

AIMS: Acute exacerbation is a major event that alters the natural course of chronic obstructive pulmonary disease (COPD), and recurrent exacerbation results in worse clinical outcomes and greater economic consequences. While some patients suffer frequent exacerbations, others experience no exacerbations; this study was designed to detect proteins that were differentially abundant in COPD frequent exacerbators and assess whether those expression profiles are unique among COPD patients. MAIN
METHODS: Tandem mass tag labeled quantitative proteomics combined with two-dimensional liquid chromatography-tandem mass spectrometry was used to detect the changes in the lung proteome in COPD frequent exacerbators and infrequent exacerbators. A series of bioinformatics analyses were performed to screen potential signatures of COPD frequent exacerbations. The accuracy of proteomic results was further verified by western blot studies. KEY
FINDINGS: Compared with infrequent exacerbators, 23 proteins in the lung tissues from frequent exacerbators showed significant degrees of differential expression; combined bioinformatics analyses of proteome indicated that the immune network for IgA production and the phenylalanine metabolism pathway were associated with frequent exacerbations. The Western blot analysis confirmed the expression pattern of three significantly regulated proteins (HLA-DQA1, pIgR and biglycan). SIGNIFICANCE: These findings indicate that immune response might play a key role in the pathophysiological mechanisms of COPD frequent exacerbations. Our results make a crucial contribution to the search for a comprehensive understanding of potential pathophysiological mechanisms associated with the frequent exacerbations of COPD, and might provide guidance for treating frequent exacerbations.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  COPD; Frequent exacerbators; Human lung tissue; Immune response; Proteomic profile

Mesh:

Substances:

Year:  2019        PMID: 31121174     DOI: 10.1016/j.lfs.2019.05.047

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures.

Authors:  Haruhiko Furusawa; Jonathan H Cardwell; Tsukasa Okamoto; Avram D Walts; Iain R Konigsberg; Jonathan S Kurche; Tami J Bang; Marvin I Schwarz; Kevin K Brown; Jonathan A Kropski; Mauricio Rojas; Carlyne D Cool; Joyce S Lee; Paul J Wolters; Ivana V Yang; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

2.  Lung proteomic biomarkers associated with chronic obstructive pulmonary disease.

Authors:  Yu-Hang Zhang; Michael R Hoopmann; Peter J Castaldi; Kirsten A Simonsen; Mukul K Midha; Michael H Cho; Gerard J Criner; Raphael Bueno; Jiangyuan Liu; Robert L Moritz; Edwin K Silverman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-20       Impact factor: 5.464

Review 3.  Recent evidence from omic analysis for redox signalling and mitochondrial oxidative stress in COPD.

Authors:  Sharon Mumby; Ian M Adcock
Journal:  J Inflamm (Lond)       Date:  2022-07-11       Impact factor: 6.283

Review 4.  Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance.

Authors:  Sandeep Appunni; Muni Rubens; Venkataraghavan Ramamoorthy; Vivek Anand; Madhuram Khandelwal; Alpana Sharma
Journal:  Mol Cell Biochem       Date:  2021-06-28       Impact factor: 3.396

5.  Identification of Proteomic Signatures in Chronic Obstructive Pulmonary Disease Emphysematous Phenotype.

Authors:  Shuang Bai; Rui Ye; Cuihong Wang; Pengbo Sun; Di Wang; Yong Yue; Huiying Wang; Si Wu; Miao Yu; Shuhua Xi; Li Zhao
Journal:  Front Mol Biosci       Date:  2021-07-01

6.  AGR3 Regulates Airway Epithelial Junctions in Patients with Frequent Exacerbations of COPD.

Authors:  Rui Ye; Cuihong Wang; Pengbo Sun; Shuang Bai; Li Zhao
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.